Shareholders sued over what they saw as a breach of fiduciary duties by the board of directors regarding the drug Anktiva, ...

OncoZenge Provides Market and Strategy UpdateOncoZenge AB (publ) (“OncoZenge” or “the Company”) today announced a comprehensive market and strategy update after successfully securing full funding for ...

OncoZenge AB (publ) ("OncoZenge" or "the Company") today announced a comprehensive market and strategy update after successfully securing full funding for its BupiZenge Phase 3 clinical trial aimed at ...